Press Release Details

MedReleaf comments on decision to rescind Obama-era memo on U.S. federal cannabis law enforcement

4 Jan 2018.

MARKHAM, ON, Jan. 4, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, today provided an update in response to the recent U.S. federal cannabis law enforcement memo issued by United States Attorney General, Jeff Sessions

The Company does not have, and does not intend to engage in, any direct, indirect or ancillary involvement in the U.S. cannabis industry until it is federally legal to do so.  As a result of MedReleaf's approach, any changes to the enforcement of United States federal laws on marijuana will not affect the Company's business.

About MedReleaf Corp.

MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world.  The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is an R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis.  Sourced from around the world and carefully cultivated in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf

SOURCE MedReleaf Corp.

Dennis Fong, Investor Relations, investorrelations@medreleaf.com, 416-283-9930